Area of research
Psychiatry and Mental health · Physiology
Research interest
Research interests include Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Medical Imaging Techniques and Applications, and Intracerebral and Subarachnoid Hemorrhage Research.
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium
Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study
Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study
Quantitative Brain Amyloid PET
Quantification supports amyloid-PET visual assessment of challenging cases: results from the AMYPAD-DPMS study
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients
Analysis of Psychological Symptoms Following Disclosure of Amyloid–Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline
Harmonization of brain PET images in multi-center PET studies using Hoffman phantom scan
Differential associations between regional amyloid PET and Alzheimer’s disease polygenic risk scores
Comparing parametric methods for longitudinal measurement of β‐amyloid pathology with PET in elderly individuals
Quantification of amyloid PET for future clinical use: a state-of-the-art review
A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images
Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load
Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia
A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer’s Disease
Estimation of amyloid distribution by [18F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition
Performance of [<sup>18</sup>F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA‐AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection
No Association of Lower Hippocampal Volume With Alzheimer’s Disease Pathology in Late-Life Depression